Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
暂无分享,去创建一个
K. Chayama | Y. Karino | J. Toyota | K. Ikeda | H. Kumada | F. Mcphee | E. Hughes | Shoichi Takahashi | Hideaki Watanabe | H. Ishikawa | Shoichi Takahashi